Publications

July 1, 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

July 1, 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

July 1, 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

July 1, 2021

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Publications

September 1, 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

September 1, 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

September 1, 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

September 1, 2020

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Publications

June 9, 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

June 9, 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

June 9, 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

June 9, 2020

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Publications

May 29, 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

May 29, 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

May 29, 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

May 29, 2019

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Publications

April 25, 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

April 25, 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

April 25, 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

April 25, 2019

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Publications

April 26, 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

April 26, 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

April 26, 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

April 26, 2018

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Publications

February 22, 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

February 22, 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

February 22, 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

February 22, 2018

Immobilized fibrinogen activates human platelets through glycoprotein VI

Publications

June 9, 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

June 9, 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

June 9, 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

June 9, 2017

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Publications

May 1, 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

May 1, 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

May 1, 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

May 1, 2016

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Publications

September 14, 2015

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Publications

September 14, 2015

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Publications

September 14, 2015

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Publications

September 14, 2015

Publications

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Population Pharmacokinetic/ Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Immobilized fibrinogen activates human platelets through glycoprotein VI

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

International Journal of Stroke: Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Journal of Thrombosis and Haemostasis: Antiplatelet drugs: which targets for which treatments?

Navigation

Contact Us